TriSalus Life Sciences

TLSI

Market cap $321M

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company's portfolio of pressure-enabled drug delivery systems designed to improve therapy delivery in varying vascular environments. Building on the success of the TriNav platform, TriNav XP was.

TriSalus Life Sciences, Inc. ( TLSI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Mary Szela - CEO, President & Director David Patience - Chief Financial Officer Richard Marshall Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Nelson Cox - Lake Street Capital Markets, LLC, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Carl Byrnes - Northland Capital Markets, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Shaymus Contorno - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to TriSalus Life Sciences' Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.4 per share a year ago.

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. “TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinica.

TriSalus Life Sciences, Inc. ( TLSI ) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization November 12, 2025 10:00 AM EST Company Participants Mary Szela - CEO, President & Director Richard Marshall Andrea Marasso Conference Call Participants Nicole Lamparello Francis Kang Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Canaccord Genuity MedTech, Diagnostics and Digital Health.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (Universit.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the foll.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Participant Mary T.